Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring

Abstract

Liquid biopsy consists in a simple blood sampling that allows to analyze cell free DNA (cfDNA), containing specific genomic clues released by the tumor into the bloodstream. In this review, we shall focus on the analysis of cfDNA in lymphoma and, in particular, on its application in the genotyping and monitoring of two common types of B-cell lymphoma, i.e., diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). From a diagnostic standpoint and based upon the current international guidelines, lymphoma diagnosis has so far relied on the analysis of the tissue biopsy. From a molecular viewpoint, though, the tissue biopsy does not reflect the entire molecular heterogeneity of lymphomas. In fact, in an individual patient, lymph nodes at different anatomical sites, as well as different areas of the same lymph node, may show different genetic profiles. Consequently, molecular analysis of genomic DNA extracted from a single lymph node biopsy may not recapitulate the whole mutational landscape of the disease. Liquid biopsy may overcome this hurdle, since cfDNA is released by all tumoral cells and can reveal the entire molecular complexity of lymphomas. From a translational perspective, liquid biopsy may also be used to evaluate clonal evolution, response to therapy and minimal residual disease. Consistently, in DLBCL as well in cHL, the drop of the mutational burden during the treatment course provides complementary information to conventional imaging techniques. The integration of liquid biopsy with imaging techniques may prove useful for a better prediction of patients’ outcome and for a better treatment tailoring.

Keywords

Liquid biopsy / lymphoma / precision medicine

References

[1] Merker JD,Compton C,Hurley P.Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review..J Clin Oncol2018;36:1631-41

[2] Siravegna G,Siena S.Integrating liquid biopsies into the management of cancer..Nat Rev Clin Oncol2017;14:531-48

[3] Arzuaga-Mendez J,Lopez-Lopez E,García-Ruiz JC.Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: a systematic review..Crit Rev Oncol Hematol2019;139:7-15

[4] Melani C,Roschewski M.Liquid biopsy in non-Hodgkin’s lymphoma..Hematol Oncol.2019;37 Suppl 1:70-4

[5] Crombie J.The emerging role of liquid biopsies in lymphoproliferative disorders..Curr Hematol Malig Rep2019;14:11-21

[6] Wan JCM,Garcia-Corbacho J,Brenton JD.Liquid biopsies come of age: towards implementation of circulating tumour DNA..Nat Rev Cancer2017;17:223-38

[7] Snyder MW,Hill AJ,Shendure J.Cell-free DNA Comprises an in vivo nucleosome footprint that informs its tissues-of-origin..Cell2016;164:57-68 PMCID:PMC4715266

[8] Rossi D,Spina V.Methods for measuring ctDNA in lymphomas..Methods Mol Biol2019;1881:253-65

[9] El Messaoudi S,Mouliere F.Circulating cell free DNA: preanalytical considerations..Clin Chim Acta2013;424:222-30

[10] Streck (2014) Cell-free DNA BCT: instructions for use. Omaha, NE. Available from: https://www.streck.com/news/2016-09-19-Streck-announces-blood-collection-tube-forcell-free-plasma-RNA.aspx. [Last accessed on 2 Sep 2019]

[11] Qiagen (2013) QIAamp® circulating nucleic acid handbook. 3rd ed. Available from: https://www.qiagen.com/us/resources/download.aspx?id1/40c4b31ab-f4fb-425f-99bf-10ab9538c061&lang1/4en. [Last accessed on 2 Sep 2019]

[12] Pérez-Barrios C,Torrente M,Calvo V.Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing..Transl Lung Cancer Res2016;5:665-72 PMCID:PMC5233878

[13] Kurtz DM,Bratman SV,Liu CL.Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing..Blood2015;125:3679-87 PMCID:PMC4463733

[14] Roschewski M,Pittaluga S,Pepin F.Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study..Lancet Oncol2015;16:541-9 PMCID:PMC4460610

[15] Rossi D,Bruscaggin A.Liquid biopsy in lymphoma..Haematologica2019;104:648-52 PMCID:PMC6442975

[16] Newman AM,To J,Eclov NC.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage..Nat Med2014;20:548-54 PMCID:PMC4016134

[17] Tilly H,Vitolo U,Meignan M.Diffuse large B-cell lymphoma: ESMO Clinical Practice Guidelines..Ann Oncol2015;26:v116-25

[18] Eichenauer DA,André M,Hutchings M.Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2018;29:iv19-29

[19] Araf S,Korfi K,Kotsiou E.Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma..Leukemia2018;32:1261-5 PMCID:PMC5940637

[20] Rossi D,Spaccarotella E,Zanni M.Diffuse large B-cell lymphoma genotyping on the liquid biopsy..Blood2017;129:1947-57

[21] Kurtz DM,Jin MC,Craig AFM.Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma..J Clin Oncol2018;36:2845-53 PMCID:PMC6161832

[22] Pasqualucci L.The genetic landscape of diffuse large B-cell lymphoma..Semin Hematol2015;52:67-76 PMCID:PMC4646421

[23] Spina V,Cuccaro A,Di Trani M.Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma..Blood2018;131:2413-25

[24] Gallamini A,Merli F,Bosi A.The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease..Haematologica2006;91:475-81

[25] Gallamini A,Rigacci L,Merli F.Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study..J Clin Oncol2007;25:3746-52

[26] Adams HJ,Kwee TC.Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis..Br J Haematol2015;170:356-66

[27] Kurtz DM,Scherer F,Jin MC.Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction..Cell2019;178:699-713.e19

[28] ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy in Mature B-cell Tumors. Identifier NCT03280394. Available from: https://clinicaltrials.gov/ct2/show/NCT03280394. [Last accessed on 2 Sep 2019]

[29] ClinicalTrials.gov. National Library of Medicine (U.S.). Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA). Identifier NCT02883517. Available from: https://clinicaltrials.gov/ct2/show/NCT02883517. [Last accessed on 2 Sep 2019]

[30] ClinicalTrials.gov. National Library of Medicine (U.S.). Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE). Identifier NCT03702309. Available from: https://clinicaltrials.gov/ct2/show/NCT03702309. [Last accessed on 2 Sep 2019]

[31] Wedge E,Garde C,Tholstrup D.Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma..Am J Hematol2017;92:689-94

[32] Kristensen LS,Kristensen SS,Harsløf LB.Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma..Clin Epigenetics2016;8:95 PMCID:PMC5015248

[33] Hallmans G.Best practices for establishing a biobank..Methods Mol Biol2011;675:241-60

[34] Baker M.Biorepositories: building better biobanks..Nature2012;486:141-6